The Role of α7-Nicotinic Acetylcholine Receptors in the Pathophysiology and Treatment of Parkinson’s Disease DOI Open Access
Eslam El Nebrisi, Yosra Lozon, Murat Öz

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(7), С. 3210 - 3210

Опубликована: Март 30, 2025

The α7 nicotinic acetylcholine receptor (α7-nAChR) is a pivotal regulator of neurotransmission, neuroprotection, and immune modulation in the central nervous system. This review explores its structural functional attributes, highlighting therapeutic potential neurodegenerative disorders, particularly Parkinson’s disease (PD). α7-nAChRs mediate synaptic plasticity, modulate inflammatory responses, influence dopamine release, positioning them as promising pharmacological target. Positive allosteric modulators (PAMs) enhance α7-nAChR activity mainly by reducing desensitization, offering superior approach compared with direct agonists. Emerging preclinical studies suggest that activation mitigates dopaminergic neurodegeneration, improves L-dopa-induced dyskinesia, reduces neuroinflammation. Despite findings, clinical trials have yielded mixed results, necessitating further research into optimizing α7-targeted therapies. underscores significance PD pathophysiology highlights future directions for their translational neuroprotection symptomatic relief.

Язык: Английский

The Role of α7-Nicotinic Acetylcholine Receptors in the Pathophysiology and Treatment of Parkinson’s Disease DOI Open Access
Eslam El Nebrisi, Yosra Lozon, Murat Öz

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(7), С. 3210 - 3210

Опубликована: Март 30, 2025

The α7 nicotinic acetylcholine receptor (α7-nAChR) is a pivotal regulator of neurotransmission, neuroprotection, and immune modulation in the central nervous system. This review explores its structural functional attributes, highlighting therapeutic potential neurodegenerative disorders, particularly Parkinson’s disease (PD). α7-nAChRs mediate synaptic plasticity, modulate inflammatory responses, influence dopamine release, positioning them as promising pharmacological target. Positive allosteric modulators (PAMs) enhance α7-nAChR activity mainly by reducing desensitization, offering superior approach compared with direct agonists. Emerging preclinical studies suggest that activation mitigates dopaminergic neurodegeneration, improves L-dopa-induced dyskinesia, reduces neuroinflammation. Despite findings, clinical trials have yielded mixed results, necessitating further research into optimizing α7-targeted therapies. underscores significance PD pathophysiology highlights future directions for their translational neuroprotection symptomatic relief.

Язык: Английский

Процитировано

0